para-Aminosalicylic acid (PAS) is a second-line anti-tubercular drug that is used for the treatment of 14 drug-resistant tuberculosis (TB). PAS efficacy in the treatment of TB is limited by its lower potency 15
Introduction 27
Mycobacterium tuberculosis is responsible for approximately 10.4 million new cases of active 28 tuberculosis (TB) and 1.3 million deaths annually (WHO, 2017) . While TB chemotherapeutic 29
intervention is highly successful in curing drug-susceptible TB infections, therapy is challenging, in 30 part, because it requires a minimum of 6 months of treatment with drugs associated with adverse 31
reactions. In addition, the emergence of drug-resistant strains of M. tuberculosis has dramatically 32 increased the complexity and cost of TB treatment (Gandhi et al. 2006 , Gehre et al. 2016 . Therefore, 33
the development of more efficacious TB chemotherapy regimens is imperative to improve treatment 34 outcomes. 35 para-Aminosalicylic acid (PAS) was the second drug to be developed exclusively for TB 36 chemotherapy (Lehmann 1946) . Although PAS was a cornerstone agent of early multidrug TB 37 therapies, the introduction of more potent anti-tubercular agents into TB treatment regimens greatly 38 diminished its usage (Minato et al. 2015) . Emergence of M. tuberculosis strains with resistance to 39 first-line anti-tubercular agents led to the resurgence of PAS as an second-line drug to treat infections 40 that failed to respond to standard short-course therapy (Donald and Diacon 2015) . However, 41 compared to many other anti-tubercular drugs, PAS is less potent and is associated with a high rate of 42 gastrointestinal distress which limits its use to the treatment of multi-drug resistant TB for which 43 there are few other treatment options (Zumla et al. 2013 ). Thus, it is important to develop novel 44 strategies to enhance PAS potency, limit adverse reactions and improve treatment success rates. 45
Until recently, little was known regarding the mode of action of PAS. PAS is a selective 46 antimetabolite of the M. tuberculosis folate metabolic pathway acting as a structural analog of the 47 folate precursor para-aminobenzoic acid (PABA) (Figure 1 ) (Chakraborty et al. 2013, Minato, 48 Thiede, Kordus, McKlveen, Turman and Baughn 2015) . PAS is sequentially converted to 2'-49 hydroxy-7,8-dihydropteroate and 2'-hydroxy-7,8-dihydrofolate by enzymes in the M. tuberculosis 50 folate metabolic pathway (Figure 1) amine is incapable of nucleophilically reacting with DHPPP during the first step of PAS 68 bioactivation (Figure 1 ). Since addition of methionine can potentially enhance the ability of M. 69 tuberculosis to methylate PAS by increasing S-adenosylmethionine (SAM) abundance, it is possible 70 that methionine promotes inactivation of PAS through N,N-dimethylation by an unidentified 71 methyltransferase. 72
In the present study we screened approximately 10,000 independent Mycobacterium bovis BCG 73 transposon insertion mutants (BCG::himar1) to identify genetic determinants associated with 74 methionine-mediated PAS antagonism. In parallel to analysis of BCG::himar1 mutants, we 75 characterized factors that affect PAS susceptibility in M. tuberculosis for their involvement in 76 methionine-mediated PAS antagonism. Our findings reveal the importance of folate precursor 77 biosynthesis and methionine transport in methionine-mediated PAS antagonism. 78
Materials and Methods 79
Chemical Reagents 80 3 All chemical reagents except for 2'-hydroxy-pteroate (pterin-PAS) were purchased from Sigma-81
Aldrich. Pterin-PAS was synthesized by Drs. Richard Lee and Ying Zhao at St Jude Children's 82
Research Hospital by using a similar synthesis method reported elsewhere (Zhao et al. 2016) . 83
Bacterial Strains and Growth Conditions 84
Bacterial strains utilized in this study are described in Table 1 BCG::himar1 mutants as described previously (Kriakov et al. 2003 , Rubin et al. 1999 ). Transduced 106 cells were plated onto 7H10 agar containing kanamycin and 10 µg/ml methionine. Approximately 107 10,000 mutant strains were screened by picking and patching onto 7H10 agar supplemented with 108 methionine (Met plates) and onto 7H10 agar plates additionally amended with 5 µg/ml PAS (Met-109 PAS plates). Mutant strains that grew on the Met plates, but were inhibited for growth the Met-PAS 110 plates, were selected for secondary screening following the same protocol. PAS susceptibility was 111 assessed for strains that passed the secondary screen. himar1 insertion sites were determined as 112 previously described ( 
Determination of Minimum Inhibitory Concentrations 121
The minimum inhibitory concentrations (MIC) of anti-tubercular compounds were determined as 122 previously described (Dillon et al. 2014 ). Briefly, for determination of the MIC in liquid culture, 2-123 fold dilution series of drugs in 7H9 medium were prepared. Logarithmically growing Mycobacterium 124 strains were inoculated into the drug-containing 7H9 medium in 30-ml square bottles (Nalgene) to an 125 optical density (OD 600 ) of 0.01. OD 600 were measured after shaking (100 rpm) at 37ºC for 14 days. 126
The liquid MIC 90 was defined as the minimum concentration of drug required to inhibit at least 90% 127 of growth relative to growth in the no-drug control cultures. For determination of the agar plate MIC, 128 logarithmically growing M. bovis BCG strains were serially-diluted and inoculated onto 7H10 agar 129 plates containing drug in 2-fold dilution series. The agar plate MIC was determined by visually 130
inspecting growth relative to growth on the no-drug control plates after grown at 37ºC for 21 days. 131
All anti-tubercular compounds employed in this study were dissolved in DMSO. The highest 132 concentration of DMSO in the growth media was 2.5%. 133
Analysis of Growth Kinetics 134
Logarithmically growing Mycobacterium strains were washed twice in an equal volume of fresh 135 medium. Cells were diluted to an OD 600 of 0.01 in 30-ml square bottles (Nalgene) and supplements 136 with or without drug were added at the described concentrations. Cultures were shaken (100 rpm) 137
and OD 600 were measured at various time points over a 14-day time-course. 138
Methionine Utilization Experiments 139
M. bovis BCG strains were grown to mid-log phase in 7H9 broth and washed twice with sulfate-free 140
Sautons medium. Resuspended cells were diluted to an OD 600 of 0.01 in sulfate-free Sautons 141 medium. Cultures were then incubated for 5 days to exhaust remaining sulfur. Exhausted cells were 142 aliquoted into 30-ml square bottles (Nalgene) and sulfur-containing metabolites were added at the 143 given concentrations. Cultures were incubated at 37ºC and shaken (100 rpm). The fold-change in 144 OD 600 (as a ratio of the final OD 600 /initial OD 600 ) was assessed following 1 week of incubation after 145 the addition of metabolites. 146
Results 147

Identification of M. bovis BCG genes involved in methionine-mediated antagonism of PAS 148
A library of M. bovis BCG transposon insertion mutant strains was constructed using the phAE180 149 mycobacteriophage containing a mariner-family transposable element. To identify genes associated 150 with methionine-mediated PAS antagonism, approximately 10,000 BCG::himar1 mutants were 151 screened following the approach outlined in Figure 2 . BCG_3282c plays a major role in methionine-mediated antagonism of PAS. We also assessed the 164 susceptibility of each mutant strain to PAS by measuring PAS MICs on 7H10 agar plates (Table 2) . 165
We observed the BCG_3282c mutant possessed wild-type PAS susceptibility suggesting this 166 mutation is associated exclusively with methionine-mediated PAS antagonism. 167
Although most mutant strains that were analyzed showed a similar level of PAS tolerance as the 168 parent M. bovis BCG, four mutants (with transposon insertions in bioB, ftsH, metB, and BCG_1906c) 169
were found to be more susceptible to PAS in the absence of methionine, indicating that the disrupted 170 genes may be involved in intrinsic resistance to PAS (Table 2) . 171
BCG_3282c is essential for methionine-mediated antagonism of PAS in M. bovis BCG. 172
Based upon the observation that methionine failed to antagonize PAS activity in the BCG_3282c 173 mutant, we further characterized the function of this gene. BCG_3282c::himar1 strain is specifically impaired for methionine-mediated PAS antagonism. 190
Because methionine antagonism is selectively perturbed in the BCG_3282c::himar1 mutant, we 191
hypothesized that BCG_3282c may be the methionine transporter. M. tuberculosis is known to utilize 192 reverse transsulfuration to assimilate sulfur from methionine which can serve as the sole source of 193 sulfur for this bacterium (Wheeler et al. 2005 ). Therefore, we tested whether disruption of 194
BCG_3282c would affect the ability of the bacilli to assimilate sulfur derived from methionine. 195
When M. bovis BCG and the BCG_3282c::himar1 disruption strain were grown in sulfate-free 196
Sautons medium, growth of both strains was limited (maximum OD 600 = 0.3). Upon addition of 197 sodium sulfate to the medium, both strains resumed growth and achieved typical growth yields 198 confirming these strains were previously starved for sulfur ( Figure. 3B) . When methionine was 199 added to sulfur starved M. bovis BCG, growth also resumed in a dose-dependent manner producing 200 similar growth yields as compared to the addition of sulfate alone. In contrast, growth of the 201
BCG_3282c::himar1 disruption strain could not be restored in the presence of methionine as the sole 202 source of sulfur, indicating that methionine is a transport substrate of BCG_3282c. These findings 203
indicate antagonism requires methionine import across the cell membrane via BCG_3282c. 204
PABA biosynthesis is indispensable for methionine-mediated PAS antagonism in M. 205 tuberculosis. 206
Our large-scale screening failed to identify genes directly involved in methionine-mediated PAS 207
antagonism. Thus, it is possible that genes involved in this process are redundant or are essential for 208 6 M. bovis BCG survival in vitro. Because addition of methionine can increase SAM levels and many 209 M. tuberculosis SAM-dependent methyltransferase genes are essential, we investigated whether the 210 ability to methylate PAS plays a role in methionine-mediated PAS antagonism. To test this, we 211 evaluated whether methionine can antagonize the activated PAS species, 2'-hydroxy-pteroate (pterin-212 PAS), in M. bovis BCG. It is known that N,N-dimethyl-PAS has no anti-tubercular activity, 213 presumably because N,N-dimethyl-PAS cannot react with DHPPP during the first step of PAS 214 bioactivation (Figure 1) . Thus, once PAS is activated to pterin-PAS, N-methylation should not affect 215 its anti-tubercular activity. We confirmed pterin-PAS was active against wild-type M. bovis BCG at a 216 comparable molar concentration to PAS (Table 3) . Surprisingly, pterin-PAS was still potently 217 antagonized by methionine suggesting methionine-mediated PAS antagonism does not occur by 218 methylation of PAS to inhibit PAS bioactivation. 219
It is also known that intracellular PABA levels affect PAS susceptibility in M. tuberculosis (Thiede, 220 Kordus, Turman, Buonomo, Aldrich, Minato and Baughn 2016). Since PABA biosynthesis is 221 essential for Mycobacterium survival in vitro, we hypothesized that methionine may affect PAS 222 activity. PabB, aminodeoxychorismate synthase, is one of the essential enzymes required to convert 223 chorismate to PABA in M. tuberculosis (Figure 4A) . Consequently, a M. tuberculosis H37Ra pabB 224 deletion strain is a PABA auxotroph and relies upon exogenous sources of PABA for growth ( Figure  225 4B). The folate precursor dihydropteroate is produced from PABA and DHPPP (Figure 4A) . We 226 found that pteroic acid, an oxidized form of dihydropteroate can also support the growth of the M. 227
tuberculosis H37Ra pabB deletion strain ( Figure 4B) . As expected, unlike PABA and pteroic acid, 228 methionine did not support the growth of the M. tuberculosis H37Ra pabB deletion strain indicating 229 that methionine alone is insufficient to fulfill cellular folate requirements in PABA starved M. 230 tuberculosis cells. Using the M. tuberculosis H37Ra Δ pabB deletion strain, we tested the requirement 231 of PABA biosynthesis on methionine-mediated PAS antagonism. We observed that methionine 232 potently antagonized PAS susceptibility in wild type M. tuberculosis H37Ra. In contrast, PAS 233 susceptibility of the M. tuberculosis H37Ra Δ pabB deletion strain was not antagonized by the 234 addition of methionine (Table 3) . Taken together, these data demonstrated that a functional PABA 235 biosynthetic pathway is essential for methionine to antagonize PAS in M. tuberculosis. 236
Biotin cofactor biosynthesis is essential for intrinsic resistance to PAS and other anti-237 tubercular drugs 238
Our screening also identified several mutations that conferred increased susceptibility to PAS even in 239 the absence of methionine. One strain, harboring a himar1 insertion within bioB, encoding biotin 240 synthase, showed increased susceptibility to PAS both in the presence and absence of methionine 241 (Table 2) . BioB is a radical SAM-dependent enzyme required for the final step in the synthesis of 242 biotin. We confirmed the bioB::himar1 strain exhibited biotin auxotrophy, which could be chemically 243
complemented by a minimum of 0.05 µg/ml biotin supplementation for restoration of growth ( Figure  244 5A). We speculated that susceptibility of the bioB::himar1 strain to PAS was dependent upon 245 intracellular concentrations of biotin. Thus, we examined the PAS susceptibility of the bioB::himar1 246 strain using media containing minimal (0.05 µg/ml) or excess (5 µg/ml) concentrations of biotin 247 ( Figure 5B) . We observed the bioB::himar1 strain was far more susceptible to PAS (8-fold decrease 248 in MIC 90 ) in minimal biotin medium, and that excess biotin medium was sufficient to restore 249 susceptibility back to near wild-type levels. Interestingly, the bioB::himar1 strain was also more 250 susceptible to sulfamethoxazole (SMX) and rifampicin (RIF), but maintained wild-type susceptibility 251
to isoniazid, indicating that alterations in susceptibility profiles are drug-specific ( Figure 5B) . 252
Discussion 253
Methionine is the only folate-dependent metabolite known to antagonize certain anti-folate drugs in 254 M. tuberculosis and other bacterial species. Interestingly, anti-folate drugs antagonized by 255 methionine are also antagonized by PABA, a folate precursor. Although the molecular mechanism of 256 PABA-mediated anti-folate antagonism is well understood, how methionine antagonizes anti-folate 257
drugs has yet to be elucidated. Our findings revealed that methionine-mediated PAS antagonism is 258 linked to synthesis of folate precursors. 259
One strain isolated from our screen harboring a himar1 disruption within the predicted amino acid 260
permease BCG_3282c fully sensitized M. bovis BCG to PAS in the presence of normally antagonistic 261 concentrations of methionine. In addition, the himar1 disruption within BCG_3282c prevented M. 262
bovis BCG from assimilating sulfur derived from methionine. BCG_3282c belongs to the APC 263 superfamily of transporters and our data suggested that BCG_3282c is likely responsible for uptake 264 of methionine in vitro. The most well-studied methionine transport system in bacteria is the MetD 265
ABC transporter system of the methionine uptake transporter family found in numerous organisms 266 including E. coli and even the closely related non-tubercular Mycobacterium, Mycobacterium 267
abscessus (Gál et al. 2002) . In E. coli, the MetD ABC transporter is encoded by the metNIQ gene 268
cluster (Merlin et al. 2002 predicted to be metabolically linked with methionine-mediated antagonism (Minato and Baughn 300 2017) . Further, we recently demonstrated that the biosynthetic pathway to DHPPP is essential for 301 methionine-mediated antagonism of sulfonamide action in E. coli (Minato et al. 2018 ). 302
One PAS-sensitive mutant strain with a disruption in biotin synthase (bioB) was found to be 303 auxotrophic for the cofactor biotin. Characterization of this mutant confirmed that disruption of 304 biotin biosynthesis could enhance susceptibility to PAS and rifampicin in biotin-limited conditions. 305
In M. tuberculosis, biotin is a cofactor required for acyl-CoA-carboxylase (ACC) enzymes 306 participating in key metabolic processes in lipid biosynthesis (Gago et Schnappinger 2018). It was previously reported that biotin has a vital role in methionine-mediated, 316
PAS antagonism, such that supplementation with exogenous biotin was required to observe 317 antagonism by methionine (Hedgecock 1956 ). However, our study found that biotin supplementation 318
was non-essential for methionine to antagonize PAS in M. bovis BCG suggesting that the effect of 319 biotin on PAS susceptibility is independent of the precise mechanism of antagonism, and the initial 320 observations in M. tuberculosis by Hedgecock may be a strain specific phenotype. 321
In summary, the mechanistic basis of methionine-mediated PAS antagonism was examined. Over 30 322 novel modulators of PAS susceptibility were identified by Himar1 transposon mutagenesis. 323
However, with exception of the putative amino acid permease BCG_3282c, none of the functions 324
identified were found to be directly involved in antagonism. Upon closer examination, de novo 325 biosynthesis of PABA was determined as essential for methionine-mediated antagonism, revealing a 326 previously unappreciated relationship between methionine and folate precursor synthesis. Further 327 studies are needed to reveal the precise mechanism of this process. 
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relationships that could be construed as a potential conflict of interest. 341 Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, et al. inactivation. As indicated on the left, PAS is a prodrug that must be activated by the M. tuberculosis 513 folate biosynthetic pathway. PAS is incorporated in lieu of PABA by FolP1 and glutamoylated by 514
FolC to form the antimetabolite HDHF which inhibits DfrA activity (indicated as red blunted arrows) 515 ( Camacho 2013). Previous work has identified N-methyl and N,N-dimethyl PAS species (methyl 519 groups indicated with dotted red boxes) in metabolite extracts from M. tuberculosis treated with PAS 520 (Chakraborty, Gruber, Barry, Boshoff and Rhee 2013). As N,N-dimethylation of PAS prevents 521 incorporation by FolP1, the resulting metabolite is inactive (shown on the right). This activity is 522 presumed to be dependent upon an as of yet unidentified SAM-dependent methyltransferase(s). 523
Supplementation with methionine may increase SAM pools, which could be utilized by the 524 methyltransferase(s) to inactivate PAS, thus conferring resistance. Abbreviations: PAS, para-525
